We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-11.74%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$434M
AUM Growth
-$119M
Cap. Flow
-$36.8M
Cap. Flow %
-8.48%
Top 10 Hldgs %
36.01%
Holding
127
New
20
Increased
19
Reduced
51
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$6.21M
2
NVMI
Nova
NVMI
+$5.21M
3
MAZE
Maze Therapeutics
MAZE
+$4.28M
4
IMVT icon
Immunovant
IMVT
+$4.07M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$18.2M
2
MSFT icon
Microsoft
MSFT
+$7.23M
3
META icon
Meta Platforms (Facebook)
META
+$7.12M
4
WIX icon
WIX.com
WIX
+$6.33M
5
MRVL icon
Marvell Technology
MRVL
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 73.67%
2 Technology 12.64%
3 Consumer Discretionary 2.04%
4 Communication Services 2%
5 Utilities 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
76
Structure Therapeutics
GPCR
$3.41B
$1.45M 0.33%
+84,000
New +$2.06M
WIX icon
77
WIX.com
WIX
$2.3B
$1.44M 0.33%
8,800
-30,453
-78% -$6.33M
FROG icon
78
JFrog
FROG
$9.66B
$1.37M 0.32%
42,871
-147,510
-77% -$5.13M
CAMT icon
79
Camtek
CAMT
$6.18B
$1.35M 0.31%
23,086
-13,201
-36% -$1.06M
PMN icon
80
ProMIS Neurosciences
PMN
$123M
$1.34M 0.31%
77,172
– –
SHLT
81
DELISTED
SHL Telemedicine Ltd American Depositary Shares
SHLT
$1.31M 0.3%
632,456
– –
ORIC icon
82
Oric Pharmaceuticals
ORIC
$1.15B
$1.31M 0.3%
234,834
-38,379
-14% -$336K
CEVA icon
83
CEVA Inc
CEVA
$910M
$1.25M 0.29%
+48,920
New +$1.57M
BMY icon
84
Bristol-Myers Squibb
BMY
$133B
$1.22M 0.28%
20,000
– –
VTYX
85
DELISTED
Ventyx Biosciences
VTYX
$1.16M 0.27%
1,012,749
– –
NNDM
86
Nano Dimension
NNDM
$316M
$1.14M 0.26%
+717,518
New +$1.62M
INZY
87
DELISTED
Inozyme Pharma
INZY
$1.08M 0.25%
1,191,140
– –
OTLK icon
88
Outlook Therapeutics
OTLK
$183M
$1.05M 0.24%
+857,142
New +$1.5M
ATXS
89
DELISTED
Astria Therapeutics
ATXS
$1.01M 0.23%
189,800
+50,000
+36% +$350K
CMMB
90
Chemomab Therapeutics
CMMB
$11.4M
$981K 0.23%
225,107
-78,537
-26% -$551K
CATX icon
91
Perspective Therapeutics
CATX
$332M
$980K 0.23%
460,247
– –
MRVL icon
92
Marvell Technology
MRVL
$168B
$928K 0.21%
15,070
-63,541
-81% -$6.16M
ARVN icon
93
Arvinas
ARVN
$518M
$878K 0.2%
+125,000
New +$1.96M
XENE icon
94
Xenon Pharmaceuticals
XENE
$6.06B
$876K 0.2%
26,097
-26,000
-50% -$987K
PERI icon
95
Perion Network
PERI
$375M
$835K 0.19%
102,612
– –
RGLS
96
DELISTED
Regulus Therapeutics
RGLS
$792K 0.18%
+452,845
New +$598K
LRMR icon
97
Larimar Therapeutics
LRMR
$397M
$788K 0.18%
366,304
-89,300
-20% -$282K
CRVS icon
98
Corvus Pharmaceuticals
CRVS
$1.12B
$655K 0.15%
205,859
-294,632
-59% -$1.39M
HOWL icon
99
Werewolf Therapeutics
HOWL
$17.2M
$609K 0.14%
626,810
– –
VIR icon
100
Vir Biotechnology
VIR
$1.46B
$589K 0.14%
90,855
-490,974
-84% -$4.37M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sphera Funds Management held 127 positions worth $434M, down 21% from $553M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Sphera Funds Management withdrew a net $36.8M in Q1 2025, closing 12 positions and reducing 51 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Maze Therapeutics worth $3.91M.

  • Sphera Funds Management's largest Q1 2025 buy was Maze Therapeutics: 355,554 shares worth $3.91M.
  • Sphera Funds Management added most to Sarepta Therapeutics in Q1 2025, an estimated $6.21M increase.
  • Sphera Funds Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $18.2M.
  • Sphera Funds Management fully exited Acadia Pharmaceuticals in Q1 2025, selling an estimated $5.29M.
  • Sphera Funds Management's ten largest holdings make up 36% of its $434M portfolio in Q1 2025.
  • Sphera Funds Management opened 20 new positions and closed 12 in Q1 2025.
  • Sphera Funds Management's portfolio value fell 21% quarter-over-quarter to $434M.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.